OKOğuz Karalar

Oğuz Karalar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oğuz Karalar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The value of interleukin-6 (IL-6), neuropilin-1 (Nrp-1) and amphiregulin (AREG) levels in predicting mortality in patients admitted to the intensive care unit with a pre-diagnosis of sepsis or septic shock

    by Fatma Karakoc Ozudogru, Banu Karaca, Huriye Erbak Yilmaz, Oguz Karalar, Murat Aksun, Kamil Gonderen

    Sepsis and septic shock are associated with high ICU mortality, and early risk stratification remains challenging. We assessed whether admission serum inte

  • The Need to Include Pregabalin in Routine Substance Screening Panels to Detect Non-Therapeutic Use and Abuse

    by Saliha Aksun, Başak Bağci, Oğuz Karalar, Murat Aksun, Barış Karadaş, Faruk Yavuz, Aslı Tuğba Esen, Mert Üğe, Figen Narin

    Pregabalin, prescribed for various neurological and psychiatric conditions, has demonstrated increasing potential for abuse. Despite its psychoactive effects and growing misuse, pregabalin remains absent from standard urine drug screening panels in Türkiye. To assess the prevalence of pregabalin abuse through comprehensive biochemistry laboratory data and to underscore the necessity of including pregabalin in routine toxicological screening protocols. This retrospective study analyzed urine drug screening results from 2019 to 2024 obtained in a tertiary hospital's biochemistry laboratory. Analysis was performed using a validated liquid chromatography system coupled with a tandem mass spectrometry method, which included pregabalin, gabapentin, and over 140 other substances. Data were stratified by year, clinical department, and co-detected substances. Urine pregabalin concentrations were statistically compared between single-use and polydrug use groups using the Mann-Whitney U-test. Pregabalin was detected in 15%-18% of analyzed urine samples annually, sometimes exceeding methamphetamine detection rates. The majority of positive cases originated from probation services and the Alcohol and Substance Use Disorder Treatment Center outpatient clinics. Notably, urine samples with co-detected substances exhibited significantly higher pregabalin concentrations (P < .05). The most frequently co-used drugs were cannabis and methamphetamines. However, a significant subgroup used pregabalin as the sole psychoactive substance. These individuals would be misclassified as "negative" in routine screening panels that exclude pregabalin. To describe this diagnostic blind spot, the term "incomplete negativity" is proposed, referring to toxicology reports that falsely appear negative due to limited panel scope, not true drug abstinence. Pregabalin abuse remains under-recognized due to current technical and regulatory limitations. Inclusion of pregabalin in routine drug panels is both feasible and urgently needed. The concept of incomplete negativity, introduced in this study, underscores the need to revise national toxicology practices and expand screening panels to include pregabalin. A multidisciplinary approach involving clinical psychiatry, medical biochemistry, and public health authorities is crucial. Recognizing this diagnostic gap is essential for effective clinical and legal responses to substance use disorders.

  • Inflammatory Mediator Levels and Postoperative Pain Following Root Canal Shaping with Different Apical Actions: A Randomized Controlled Trial

    by Mustafa Mert Tulgar, Yağmur Kılıç, Oğuz Karalar, Huriye Erbak Yılmaz, Emrah Karataşlıoğlu


  • Open Access

    Trends in pregabalin misuse and abuse: A 25-year bibliometric perspective

    by Sali̇ha Aksun, Karalar Oguz, Mert Üge, Berna Cafer

    Background: Originally classified among antiepileptic drugs, pregabalin has been prescribed for clinical conditions such as neuropathic pain, generalised anxiety disorder, and fibromyalgia. In recent years, accumulating evidence has highlighted its potential for misuse and abuse, particularly among individuals with a high prevalence of opioid dependence. This study aims to conduct a comprehensive bibliometric analysis of global research on pregabalin misuse and abuse, to identify key trends, influential contributors, and collaborative networks. Methods: Bibliometric design was employed using data retrieved from the Web of Science Core Collection database. The search was conducted in February 2025, and relevant publications were identified based on predefined inclusion and exclusion criteria. A total of 449 eligible records were exported and compiled for analysis. The bibliometric analysis was carried out using the bibliometrix R package and its Web-based interface Biblioshiny, both operating within the RStudio environment. Results: The analysis revealed a notable increase in scientific output on pregabalin misuse and dependence, particularly after 2010. The United States emerged as the most prolific and central country within the global collaboration network, followed by the United Kingdom, Germany, and France. Leading authors and institutions were concentrated in specific academic clusters. Keywords such as "abuse," "addiction," and "opioids" have shown an increasing trend since 2016. Conclusions: This study highlights the growing academic interest in the misuse and abuse potential of pregabalin, particularly over the past decade. The findings reveal a centralised research structure, with significant contributions from high-capacity countries such as the United States, the United Kingdom, and Germany. Emerging participation from developing countries, including Türkiye, underscores a broadening global awareness of the issue. The results emphasise the importance of interdisciplinary collaboration, policies, and the critical role of clinical laboratories in monitoring pregabalin-related risks.

  • Yasadışı Madde Analizlerinde Preanalitik Evre

    by Saliha Aksun, Başak Bağcı, Leyla Demir, Furkan Oğuzhan Karalar, Murat Aksun

    Uyuşturucu ve uyarıcı madde çalışmalarında, analiz evresinin güvenliği ve doğruluğu yanında, preanalitik evrenin de laboratuvar uzmanı tarafından kontrol altında tutulması oldukça önemlidir. Bu süreçte, analizi isteyen klinik birim ile iş birliği içinde olmak ve uygun şartları, iş akışlarını birlikte planlamak en uygun yöntem olacaktır. Preanalitik evre; uygun numunenin belirlenmesi, test panelinin doğru olarak yapılandırılması, bilgi işlem sistemi ile ilgili düzenlemeler, numunelerin kimliklendirilmesi, gözetim altında örnek alınabilmesi için gerekli fiziksel düzenlemelerin kontrolü, olası hile yöntemlerinin önlenebilmesi için tedbir alınmasının sağlanması, hasta onamının alınması, numunenin güvenli transferi, örnek teslim alma ve kayıt sürecinin yapılandırılması, analiz öncesinde örneklerin güvenli saklanması süreçlerinin tamamını içermektedir.